Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06615596 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

Study acronym: DESTINATION
StatusRecruiting
PhaseEarly Phase 1
Started2025-08-05
View on ClinicalTrials.gov ↗

Amendment history

2026-06-02
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2029-01→2029-01-01
Completion date2029-12→2029-12-31
Start dateestimated 2025-01→confirmed 2025-08-05
Study sitesdetails revised at 12 of 12 sites
2024-09-24
Original filing
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patients to unnecessary bleeding risks. This international, multicenter, randomized controlled trial aims to compare thromboembolic and bleeding event risks between patients who continue and discontinue anticoagulation after ablation. The study involves 3,160 AF patients, all free of AF recurrence within 6 months to 1 year after ablation. Smart wearable monitors will track recurrence, and patients are followed for 24 months to assess event rates. Findings may reshape anticoagulation guidelines, improving clinical practice for AF patients worldwide.
Trial Details
NCT Number NCT06615596
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Atrial Fibrillation (AF)
Enrollment 3,160 participants
Start Date 2025-08-05
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04